Share
News
-
24 May 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Xeplion®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Xeplion®. The product is eligible for general reimbursement from 30 May 2011.
-
06 May 2011 /Prices and reimbursement
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)
At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B.
-
05 May 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Trobalt®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Trobalt®. The product is eligible for general reimbursement from 16 May 2011.
-
20 April 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Grazax®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Grazax®. The product is eligible for general conditional reimbursement from 2 May 2011.
-
14 April 2011 /Prices and reimbursement
Use the conditional reimbursement scheme correctly – the opposite is misuse of society’s money and puts patient safety at risk
The Danish Medical Association and the Danish Medicines Agency urge doctors to use the conditional reimbursement scheme correctly - the opposite is misuse of society’s money and puts patient safety at risk
-
14 March 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Brilique®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Brilique®. The product has been granted general reimbursement.
-
03 March 2011 /Prices and reimbursement
The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)
Clinical studies have called into question the efficacy of glucosamine for the alleviation of painful osteoarthritis. This has contributed to the Danish Medicines Agency’s decision to initiate ad hoc reassessment of glucosamine-containing medicines, which today have general conditional reimbursement when prescribed for the alleviation of symptoms of mild to moderate osteoarthritis and when prescribed to old-age pensioners.
-
22 February 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Sycrest®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Sycrest®. The product has been granted general reimbursement.
-
22 February 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Targin®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Targin®. The product is neither eligible for general nor general conditional reimbursement.
-
15 February 2011 /Prices and reimbursement
Applications for general reimbursement in 2010
In 2010, the Danish Medicines Agency reviewed 21 cases on general reimbursement for medicines. Nine medicines were granted general reimbursement or general conditional reimbursement, and the remaining 12 medicines were refused general reimbursement, one of which maintained general conditional reimbursement.
-
02 February 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Palexia Depot®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Palexia Depot®. The product has been granted general reimbursement.
-
11 January 2011 /Prices and reimbursement
Reassessment of reimbursement status of medicines for treatment of depression and anxiety disorders
On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N
-
20 October 2010 /Prices and reimbursement
General reimbursement for medicines containing losartan in combination with hydrochlorothiazide
Patients can now receive general reimbursement for all medicines containing losartan in combination with hydrochlorothiazide. This also includes medicines containing a combination of losartan 100 mg and hydrochlorothiazide 12.5 mg
-
14 June 2010 /Prices and reimbursement
Change of the reimbursement for certain cardiovascular products as of 15 November 2010
The Reimbursement Committee and the Danish Medicines Agency have reviewed some of the medicinal products used for the treatment of cardiovascular disease (antihypertensives) in order to assess whether they meet the criteria for public reimbursement. The medicinal products concerned are the so-called angiotensin II antagonists and renin inhibitors.
-
14 June 2010 /Prices and reimbursement
Changes in reimbursements for anti-ulcer medicines
The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of heartburns, sour eructations and ulcers ('acid-related disorders') in order to assess whether they meet the criteria for public reimbursement.
-
03 June 2010 /Prices and reimbursement
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)
The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.
-
21 April 2010 /Prices and reimbursement
Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists
On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.
-
09 April 2010 /Prices and reimbursement
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)
The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders) was open for consultation until 15 March 2010.
-
31 March 2010 /Prices and reimbursement
Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors).
-
24 March 2010 /Prices and reimbursement
The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X
On 8 March 2010, a number of pharmaceutical companies put generic copies of the angiotensin II antagonist losartan on the market at prices comparable to those of the cheapest ACE inhibitors.
